PolarityBio Announces FDA Acceptance for Filing of SkinTE® BLA with Priority Review in Diabetic Foot Ulcers
BLA FilingSkinTE®Positive
AI Analysis
Summary
PolarityBio announced FDA acceptance of a BLA for SkinTE® in diabetic foot ulcers with priority review status and a PDUFA target action date of March 16, 2027.
Outcome Details
FDA acceptance for filing with priority review
Importance:8/10
Sentiment:
0.75
FDABLAPriority ReviewDiabetic Foot UlcersRegulatory
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 15, 2026 11:02 AM